A Phase 3 interventional study of Secukinumab and Adalimumab in Psoriatic Arthritis, sponsored by Novartis Pharmaceuticals. Completed at 156 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-27.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing secukinumab in Arthritis, Psoriatic — 2 open to participants now, 2 under way, 1 of them phase 3. secukinumab · Arthritis, Psoriatic.
Among the 26 studies testing secukinumab in Arthritis, Psoriatic, this one is the 2nd largest by enrollment, is the only one that started in 2017, is one of 16 in phase 3, and was the 15th registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →2 of the 26 studies testing secukinumab in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University of Erlangen-Nürnberg Medical School · Sites in Germany
Ages 18–75
By country, each count listing its studies:
secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 853 is above the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 231 across the 26 interventional studies. Of the 22 that completed or were terminated, 17 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 26 have an industry lead sponsor. The 8 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
31 studies in Arthritis, Psoriatic by Novartis: 3 open now, 3 under way, none of them phase 3. Of 28 finished, 19 (68%) have results posted.
Among the 31 studies in Arthritis, Psoriatic by Novartis, this one is the 2nd largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2017, is one of 14 in phase 3, and was the 14th registered.
Novartis’s Arthritis, Psoriatic studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing secukinumab in Arthritis, Psoriatic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 31 in Arthritis, Psoriatic:
This tab as a report to print or save as PDF → With an account.
This was a randomized, double-blind, active controlled, multicenter, parallel-group study evaluating secukinumab monotherapy and adalimumab monotherapy in approximately 850 patients with active psoriatic arthritis (PsA) who are naïve to biologic therapy and are intolerant or having inadequate response to conventional disease modifying anti-rheumatic drugs (also known as non-biologic DMARDs).
The total maximum study duration, including the screening period was up to 76 weeks.
At Baseline, patients whose eligibility was confirmed were randomized to 1 of 2 groups (1:1): Group 1 (secukinumab 300 mg) or Group 2 (adalimumab 40 mg).
In order to maintain the blind, both groups received 1 or 2 placebo s.c. injections to keep consistency in the number of injections at each dosing visit. Secukinumab (300 mg) was available in 2 x 1.0 mL pre-filled syringes (PFS) and adalimumab was available in 1 x 0.4 mL PFS. Placebo (1.0 and 0.5 mL PFS) was also available.
Secukinumab 300 mg s.c injection (2 x 1 mL PFS) was administered at Baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks to Week 48.
Adalimumab 40 mg (1 x 0.4 mL PFS) was administered at Baseline followed by dosing every 2 weeks until Week 50.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Secukinumab 300 mg administered at Baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks until Week 48.
Biological: Secukinumab
Adalimumab 40 mg administered at Baseline followed by dosing every 2 weeks until Week 50.
Biological: Adalimumab
Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
Also known as: AIN457
Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Week 52
Clinical response, failure to permanently discontinue study medication prematurely, and lack of need for rescue medication was required for a patient to achieve treatment success. The primary endpoint is the proportion of patients with monotherapy ACR20 response at Week 52 where monotherapy ACR20 response is defined as meeting the following 3 conditions: 1. achieving American College of Rheumatology 20 (ACR20) response 2. no permanent study treatment (secukinumab or adalimumab) discontinuation before or at Week 50 (the last dosing visit) 3. no use of conventional disease modifying anti-rheumatic drugs (also known as non-biologic DMARDs) cDMARDs (including Methotrexate (MTX)) after Week 36 (regardless of the starting time of taking cDMARDs)
Time frame: Week 52
Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI)-90 Response at Week 52
The PASI is a system used for assessing and grading the severity of psoriatic lesions. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 to 6, and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants who achieved at least a 90 percent improvement from baseline in the PASI score.
Time frame: Week 52
Percentage of Participants Who Achieved an American College of Rheumatology 50% (ACR50) Response at Week 52
Clinical response, failure to permanently discontinue study medication prematurely, and lack of need for rescue medication was required for a patient to achieve treatment success. The secondary endpoint is the proportion of patients with monotherapy ACR50 response at Week 52 where monotherapy ACR50 response is defined as meeting the following 3 conditions: 1. achieving American College of Rheumatology 50 (ACR50) response 2. no permanent study treatment (secukinumab or adalimumab) discontinuation before or at Week 52 3. no use of conventional disease modifying anti-rheumatic drugs (also known as non-biologic DMARDs) cDMARDs (including Methotrexate (MTX)) after Week 36 (regardless of the starting time of taking cDMARDs)
Time frame: Week 52
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI Score) at Week 52
The HAQ-DI assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities. There are 20 questions in 8 categories of functioning including dressing, rising, eating, walking, hygiene, reach, grip and usual activities. The stem of each item asks 'Over the past week, "are you able to..." perform a particular task'. Each item is scored on a 4 point scale from 0 - 3, representing normal, no difficulty (0), some difficulty (1), much difficulty (2) and unable to do (3). The disability index score is calculated as the mean of the available category scores, ranging from 0 to 3. A negative change from baseline indicates improvement.
Time frame: Baseline, Week 52
Percentage of Participants Who Achieved Resolution of Enthesitis at Week 52
Enthesitis refers to inflammation of entheses, the site where ligaments or tendons insert into the bones. Resolution was defined as the absence of recorded enthesitis; conducted by the study assessor.
Time frame: Week 52
This study was conducted at 161 centers in 26 countries worldwide: Australia, Bulgaria, Canada, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, India, Israel, Italy, South Korea, Latvia, Lithuania, The Netherlands, Poland, Portugal, Russia, Slovakia, Spain, UK and USA.
| Milestone | Secukinumab 300 mg s.c. | Adalimumab 40 mg s.c. |
|---|---|---|
| Started | 426 | 427 |
| Completed | 371 | 338 |
| Not completed | 55 | 89 |
| Withdrew: Adverse event | 13 | 21 |
| Withdrew: Lack of efficacy | 11 | 23 |
| Withdrew: Lost to follow-up | 3 | 3 |
| Withdrew: Physician decision | 3 | 0 |
| Withdrew: Protocol violation | 3 | 1 |
| Withdrew: Withdrawal by subject | 22 | 41 |
Clinical response, failure to permanently discontinue study medication prematurely, and lack of need for rescue medication was required for a patient to achieve treatment success. The primary endpoint is the proportion of patients with monotherapy ACR20 response at Week 52 where monotherapy ACR20 response is defined as meeting the following 3 conditions: 1. achieving American College of Rheumatology 20 (ACR20) response 2. no permanent study treatment (secukinumab or adalimumab) discontinuation before or at Week 50 (the last dosing visit) 3. no use of conventional disease modifying anti-rheumatic drugs (also known as non-biologic DMARDs) cDMARDs (including Methotrexate (MTX)) after Week 36 (regardless of the starting time of taking cDMARDs)
| Percentage of Participants | Secukinumab 300 mg s.c. | Adalimumab 40 mg s.c. |
|---|---|---|
| Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Week 52 | 67.4 (62.8 to 71.7) | 61.5 (56.8 to 66.0) |
The PASI is a system used for assessing and grading the severity of psoriatic lesions. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 to 6, and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants who achieved at least a 90 percent improvement from baseline in the PASI score.
| Percentage of Participants | Secukinumab 300 mg s.c. | Adalimumab 40 mg s.c. |
|---|---|---|
| Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI)-90 Response at Week 52 | 65.4 (58.8 to 71.5) | 43.2 (36.5 to 50.2) |
Clinical response, failure to permanently discontinue study medication prematurely, and lack of need for rescue medication was required for a patient to achieve treatment success. The secondary endpoint is the proportion of patients with monotherapy ACR50 response at Week 52 where monotherapy ACR50 response is defined as meeting the following 3 conditions: 1. achieving American College of Rheumatology 50 (ACR50) response 2. no permanent study treatment (secukinumab or adalimumab) discontinuation before or at Week 52 3. no use of conventional disease modifying anti-rheumatic drugs (also known as non-biologic DMARDs) cDMARDs (including Methotrexate (MTX)) after Week 36 (regardless of the starting time of taking cDMARDs)
| Percentage of Participants | Secukinumab 300 mg s.c. | Adalimumab 40 mg s.c. |
|---|---|---|
| Percentage of Participants Who Achieved an American College of Rheumatology 50% (ACR50) Response at Week 52 | 49.0 (44.3 to 53.7) | 44.8 (40.1 to 49.5) |
The HAQ-DI assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities. There are 20 questions in 8 categories of functioning including dressing, rising, eating, walking, hygiene, reach, grip and usual activities. The stem of each item asks 'Over the past week, "are you able to..." perform a particular task'. Each item is scored on a 4 point scale from 0 - 3, representing normal, no difficulty (0), some difficulty (1), much difficulty (2) and unable to do (3). The disability index score is calculated as the mean of the available category scores, ranging from 0 to 3. A negative change from baseline indicates improvement.
| Unit on a scale | Secukinumab 300 mg s.c. | Adalimumab 40 mg s.c. |
|---|---|---|
| Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI Score) at Week 52 | -0.58 ± 0.027 | -0.56 ± 0.027 |
Enthesitis refers to inflammation of entheses, the site where ligaments or tendons insert into the bones. Resolution was defined as the absence of recorded enthesitis; conducted by the study assessor.
| Percentage of Participants | Secukinumab 300 mg s.c. | Adalimumab 40 mg s.c. |
|---|---|---|
| Percentage of Participants Who Achieved Resolution of Enthesitis at Week 52 | 60.5 (54.1 to 66.6) | 54.2 (48.2 to 60.2) |
Collected over Treatment emergent adverse events were collected from first dose of study treatment until 12 Weeks (84 days) following the last administration of study treatment, an average of 68 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AIN457 300 mg | 1/426 (0.2%) | 37/426 (8.7%) | 226/426 (53.1%) |
| Adalimumab 40 mg | 0/427 (0%) | 36/427 (8.4%) | 236/427 (55.3%) |
| Total | 1/853 (0.1%) | 73/853 (8.6%) | 462/853 (54.2%) |
| Event | AIN457 300 mg | Adalimumab 40 mg | Total |
|---|---|---|---|
| PneumoniaInfections and infestations | 0/426 | 3/427 | 3/853 |
| Acute myocardial infarctionCardiac disorders | 2/426 | 0/427 | 2/853 |
| SyncopeNervous system disorders | 2/426 | 0/427 | 2/853 |
| ProstatitisReproductive system and breast disorders | 0/426 | 2/427 | 2/853 |
| AnaemiaBlood and lymphatic system disorders | 1/426 | 0/427 | 1/853 |
| LymphadenopathyBlood and lymphatic system disorders | 1/426 | 0/427 | 1/853 |
| Myocardial infarctionCardiac disorders | 1/426 | 0/427 | 1/853 |
| PericarditisCardiac disorders | 1/426 | 0/427 | 1/853 |
| Abdominal painGastrointestinal disorders | 1/426 | 0/427 | 1/853 |
| Abdominal pain upperGastrointestinal disorders | 1/426 | 0/427 | 1/853 |
| Event | AIN457 300 mg | Adalimumab 40 mg | Total |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 88/426 | 84/427 | 172/853 |
| Upper respiratory tract infectionInfections and infestations | 42/426 | 54/427 | 96/853 |
| Psoriatic arthropathyMusculoskeletal and connective tissue disorders | 34/426 | 38/427 | 72/853 |
| DiarrhoeaGastrointestinal disorders | 32/426 | 37/427 | 69/853 |
| HeadacheNervous system disorders | 36/426 | 33/427 | 69/853 |
| PsoriasisSkin and subcutaneous tissue disorders | 33/426 | 34/427 | 67/853 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 29/426 | 31/427 | 60/853 |
| Back painMusculoskeletal and connective tissue disorders | 17/426 | 31/427 | 48/853 |
| Injection site reactionGeneral disorders | 4/426 | 28/427 | 32/853 |
| HypertensionVascular disorders | 27/426 | 24/427 | 51/853 |
| Age, Continuous(Years) | Secukinumab 300 mg s.c. | Adalimumab 40 mg s.c. | Total |
|---|---|---|---|
| Mean | 48.5 ± 12.38 | 49.5 ± 12.44 | 49.0 ± 12.41 |
| Sex: Female, Male(Participants) | Secukinumab 300 mg s.c. | Adalimumab 40 mg s.c. | Total |
|---|---|---|---|
| Female | 218 | 198 | 416 |
| Male | 208 | 229 | 437 |
| Race/Ethnicity, Customized(Participants) | Secukinumab 300 mg s.c. | Adalimumab 40 mg s.c. | Total |
|---|---|---|---|
| Asian | 16 | 20 | 36 |
| American Indian or Alaska Native | 0 | 1 | 1 |
| Black or African American | 3 | 2 | 5 |
| White | 402 | 391 | 793 |
| Unknown | 1 | 5 | 6 |
| Other | 4 | 8 | 12 |
Showing the first 100 of 156 sites across 26 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Apr 2017 to primary completion in Dec 2019, 32 months.
Results were first posted in Jan 2021, 1 year after primary completion. A results delay was requested in May 2020.
Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 32 months is above that.
Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab